Market Overview

The National Mesothelioma Law Firm of Baron and Budd Applauds U.S Congress for Passing High Mortality Cancer Bill Signed into Law

Mesothelioma Lawyers at Baron and Budd Applaud Passage of Bill That Will Help Fund Research for Lung Cancer

DALLAS (PRWEB) January 08, 2013

The national mesothelioma law firm of Baron and Budd commends Congress for approving a bill that will greatly aid those suffering from asbestos-related lung cancer and mesothelioma. Recently, President Barack Obama signed the High Mortality Cancer Bill into law just as the 112th congress came to a close. This piece of legislation is the first of its kind and presents a widespread research development plan to dramatically increase survival rates for high mortality cancers. The new law will give lung and pancreatic cancers priority status in research endeavors.

The High Mortality Cancer bill was incorporated in the National Defense Authorization Act of 2013, and was signed just hours before the session ended. The breakthrough legislation requires the National Cancer Institute (NCI) to create scientific frameworks for addressing cancers with survival rates of less that 50 percent, with precedence being given to patients with pancreatic and lung cancer.

After the legislation passed, Lung Cancer Alliance President and CEO Laurie Fenton Ambrose said that this legislation was the best possible present to begin the new year for all those at risk for lung cancer. The LCA began significant legislative efforts nearly six years ago.

"The War on Cancer legislation was passed in congress 40 years ago, but little progress has been made," said John Langdoc, mesothelioma lawyer at Baron and Budd. "Yet, the High Mortality Asbestos bill will bring new hope to those suffering from high-risk cancers and acknowledges lung cancer as a vital public health priority."

Currently, lung cancer's five-year survival rate is 15 percent, with the pancreatic cancer rate even lower at 5 percent. Many people only associate lung cancer with first or secondhand smoking, but asbestos exposure can also cause certain types of the deadly disease. People who were exposed to asbestos and also smoked are particularly at risk. Often, there is a stigma attached to those who suffer from lung cancer, that people somehow inflicted the disease upon themselves. However, more and more people are beginning to understand that lung cancer can affect anybody, especially those who have been in contact with asbestos-containing products or other environmental contaminants. To learn more about lung cancer survival rates, visit: http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-fact-sheet.html

The Dallas-based mesothelioma law firm of Baron and Budd has been working on behalf of mesothelioma and asbestos lung cancer patients for almost 35 years. The law firm knows how aggressive and deadly lung cancer and mesothelioma can be, and has lent its support several medical organizations to progress mesothelioma and lung cancer treatment. Baron and Budd congratulates Congress and President Obama for passing this milestone legislation and will be closely watching its development.

For more information on The High Mortality Cancer Bill and the Lung Cancer Alliance, visit: http://www.lungcanceralliance.org/blog/its-official-president-obama-signs-high-mortality-cancer-bill-into-law/

About Baron & Budd

The national mesothelioma law firm of Baron & Budd, P.C. has been “Protecting What's Right” for asbestos sufferers and their families for nearly 35 years. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exposure to asbestos. Contact Baron and Budd at 1.866.855.1229 for additional information on mesothelioma treatments, mesothelioma cancer doctors and treatment centers and mesothelioma attorneys. http://baronandbudd.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10300112.htm

 

Around the Web, We're Loving...

Get Benzinga's Newsletters